331 related articles for article (PubMed ID: 30736852)
41. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
Liu B; Hu Y; Qin L; Peng XB; Huang YX
Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
[TBL] [Abstract][Full Text] [Related]
42. Cholangiocarcinoma.
Mosconi S; Beretta GD; Labianca R; Zampino MG; Gatta G; Heinemann V
Crit Rev Oncol Hematol; 2009 Mar; 69(3):259-70. PubMed ID: 18977670
[TBL] [Abstract][Full Text] [Related]
43. Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA.
Junking M; Grainok J; Thepmalee C; Wongkham S; Yenchitsomanus PT
Tumour Biol; 2017 Oct; 39(10):1010428317733367. PubMed ID: 29034817
[TBL] [Abstract][Full Text] [Related]
44. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
Liu J; Shu J
Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
[TBL] [Abstract][Full Text] [Related]
46. Recurrent biliary dissemination of colon cancer liver metastasis: a case report.
Onishi I; Kayahara M; Takei R; Makita N; Munemoto M; Yagi Y; Kawashima A
J Med Case Rep; 2018 Oct; 12(1):314. PubMed ID: 30367665
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.
Laohaviroj M; Chamgramol Y; Pairojkul C; Mulvenna J; Sripa B
Asian Pac J Cancer Prev; 2016; 17(1):201-5. PubMed ID: 26838210
[TBL] [Abstract][Full Text] [Related]
48. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
49. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes.
Aoba T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Takahashi Y; Nimura Y; Nagino M
Ann Surg; 2013 Apr; 257(4):718-25. PubMed ID: 23407295
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy for cholangiocarcinoma: a 2021 update.
Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
[TBL] [Abstract][Full Text] [Related]
51. Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis.
Asakura H; Ohtsuka M; Ito H; Kimura F; Ambiru S; Shimizu H; Togawa A; Yoshidome H; Kato A; Miyazaki M
Hepatogastroenterology; 2005; 52(63):722-4. PubMed ID: 15966191
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the diagnostic performance of apparent diffusion coefficient (ADC) values on diffusion-weighted magnetic resonance imaging (DWI) in differentiating between benign and metastatic lymph nodes in cases of cholangiocarcinoma.
Promsorn J; Soontrapa W; Somsap K; Chamadol N; Limpawattana P; Harisinghani M
Abdom Radiol (NY); 2019 Feb; 44(2):473-481. PubMed ID: 30151713
[TBL] [Abstract][Full Text] [Related]
53. [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Shimizu J; Hayashi S; Dono K; Yasumoto T; Zenitani M; Munakata K; Watanabe N; Takamoto K; Kagawa Y; Hata T; Kawanishi K; Ikeda K; Fujita J; Akagi K; Kitada M; Shimano T
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2380-2. PubMed ID: 20037429
[TBL] [Abstract][Full Text] [Related]
54. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Louis C; Edeline J; Coulouarn C
Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
[No Abstract] [Full Text] [Related]
55. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
56. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.
Raggi C; Correnti M; Sica A; Andersen JB; Cardinale V; Alvaro D; Chiorino G; Forti E; Glaser S; Alpini G; Destro A; Sozio F; Di Tommaso L; Roncalli M; Banales JM; Coulouarn C; Bujanda L; Torzilli G; Invernizzi P
J Hepatol; 2017 Jan; 66(1):102-115. PubMed ID: 27593106
[TBL] [Abstract][Full Text] [Related]
57. De novo cholangiocarcinoma after liver transplantation in a pediatric patient.
Channabasappa N; Johnson-Welch S; Mittal N
Pediatr Transplant; 2010 Dec; 14(8):E110-4. PubMed ID: 19659806
[TBL] [Abstract][Full Text] [Related]
58. Expansion and Adoptive Transfer of Human Vδ2
Sharma A; Zumwalde NA; Gumperz JE
Methods Mol Biol; 2019; 1884():57-72. PubMed ID: 30465195
[TBL] [Abstract][Full Text] [Related]
59. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
60. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis.
Hu JH; Tang JH; Lin CH; Chu YY; Liu NJ
J Investig Med; 2018 Jan; 66(1):52-61. PubMed ID: 28912249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
